Sarepta Therapeutics, Inc. (SRPT)
NASDAQ: SRPT · Real-Time Price · USD
18.36
+0.64 (3.61%)
Sep 26, 2025, 4:00 PM EDT - Market closed
Sarepta Therapeutics Stock Forecast
Stock Price Forecast
According to 28 professional analysts, the 12-month price target for Sarepta Therapeutics stock ranges from a low of $5.00 to a high of $170. The average analyst price target of $40.61 forecasts a 121.19% increase in the stock price over the next year.
Price Target: $40.61 (+121.19%)
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for Sarepta Therapeutics stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 6 | 4 | 3 | 3 | 3 |
| Buy | 12 | 13 | 10 | 7 | 7 | 8 |
| Hold | 4 | 5 | 10 | 14 | 14 | 14 |
| Sell | 0 | 0 | 0 | 2 | 2 | 2 |
| Strong Sell | 1 | 0 | 1 | 3 | 4 | 4 |
| Total | 22 | 24 | 25 | 29 | 30 | 31 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| BMO Capital | BMO Capital | Hold → Buy Upgrades $50 | Hold → Buy | Upgrades | $50 | +172.33% | Sep 22, 2025 |
| Guggenheim | Guggenheim | Strong Buy Reiterates $22 | Strong Buy | Reiterates | $22 | +19.83% | Sep 15, 2025 |
| Leerink Partners | Leerink Partners | Hold Maintains $12 → $15 | Hold | Maintains | $12 → $15 | -18.30% | Sep 9, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Sell Reiterates $5 | Strong Sell | Reiterates | $5 | -72.77% | Aug 25, 2025 |
| B of A Securities | B of A Securities | Sell Maintains $17 → $16 | Sell | Maintains | $17 → $16 | -12.85% | Aug 21, 2025 |
Financial Forecast
Revenue This Year
2.11B
from 1.90B
Increased by 10.78%
Revenue Next Year
1.64B
from 2.11B
Decreased by -22.16%
EPS This Year
-4.49
from 2.34
EPS Next Year
2.33
from -4.49
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 2.5B | 2.4B | |||
| Avg | 2.1B | 1.6B | |||
| Low | 1.6B | 964.9M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 30.9% | 12.2% | |||
| Avg | 10.8% | -22.2% | |||
| Low | -13.3% | -54.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.58 | 6.90 | |||
| Avg | -4.49 | 2.33 | |||
| Low | -7.02 | -1.68 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.